Drugs / Mipsagargin
Mipsagargin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01056029 | Jan 2010 → Dec 2012 | cancer | GenSpera, Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02876003 | Sep 2016 → Oct 2019 | glioblastoma | GenSpera, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02607553 | Jun → Dec 2016 | clear cell renal carcinoma | GenSpera, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02381236 | Feb → Dec 2016 | prostate neoplasm | GenSpera, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02067156 | Feb 2014 → Dec 2016 | glioblastoma | GenSpera, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01734681 | May 2013 → Jan 2015 | prostate cancer | GenSpera, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01777594 | Jan 2013 → Mar 2015 | adult hepatocellular carcinoma | GenSpera, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02082691 | — | hepatocellular carcinoma | Devalingam Mahalingam | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mipsagargin | “G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle” NCT02876003 ↗ |
| Known as | G-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02381236 ↗ |
| Known as | Mipsagargina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989865 ↗ |
| Known as | Mipsagargine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989865 ↗ |
| Modality | Other / unclassified | “G-202 (mipsagargin) is a thapsigargin pro-drug” NCT01056029 ↗ |
| Route | Intravenous | “G-202 will be administered by intravenous infusion over 1 hour” NCT01056029 ↗ |